作者详细评价了Vigabatrin治疗难治的复合性、局限性癫痫(CPS)患者的长期疗效及其安全性。本组全部患者均在12周基线期和16周单盲研究后进入开标长期研究。共有89例患者进入此研究,84例完成了单盲研究。66例患者进入5～72个月(平均43个月)的长期研究。26例患者服用Vigabatrin长达5年。平均每天3g(1～4g)。15例患者撤除了一种或几种合并用药,而2例患者在长期研究 The authors evaluated in detail the long-term efficacy and safety of Vigabatrin in the treatment of refractory complex, localized epilepsy (CPS) patients. All patients in this group were enrolled in the open-label long-term study after 12 weeks of baseline and 16 weeks of single-blind study. A total of 89 patients entered the study, 84 completed a single-blind study. Sixty-six patients entered a long-term study of 5 to 72 months (mean, 43 months). Twenty-six patients took Vigabatrin for up to 5 years. Average daily 3g (1 ~ 4g). Fifteen patients had one or more combination medications removed, while two patients were on long-term studies